Abstract Body

The underlying mechanism for endothelial dysfunction and HIV-associated cardiovascular disease (CVD) remains unknown. Immune activation and chronic inflammation persist even in the setting of effectively treated HIV. T cell activation leads to T cell dysregulation and may be one underlying cause of chronic inflammation in HIV-infected individuals. The purpose of this study was to determine whether T cell activation and inflammatory markers in HIV-infected individuals are associated with endothelial dysfunction, a predictor of future cardiovascular events.

We performed a cross-sectional study of immune activation and inflammatory markers with endothelial function in 359 HIV-infected adults. Endothelial function was assessed using flow-mediated vasodilation of the brachial artery (FMD) and reactive hyperemia (RH). T-cell activation including HIV and CMV-specific responses were assessed using flow cytometry in peripheral mononuclear blood cells.

The mean age was 49 ± 10 years and 84% were male, 76% were on ART, 31% smokers, and 18% with hepatitis C.  The median FMD was 4.0% (IQR 2.6, 5.5) and the median RH was 57% (IQR 45, 79).  After multivariable adjustment for demographics, traditional CV and HIV risk factors, CMV IgG was the only inflammatory marker associated with impaired FMD (-11.7% per doubling, p = 0.002). In comparison, higher TNF-α (-44.5% per doubling, p = 0.007) and higher neopterin (13.9% per doubling, p = 0.035) were associated with lower (worsened) RH. Other inflammatory markers including hsCRP, IL-6, sCD163, and D-dimer were not associated with FMD or RH. Only CD4+IFN+ (CMV specific) T cell activation was associated with lower RH (-4.5% per doubling, p = 0.028) and none of the other assessments of T cell activation were predictive of either FMD or RH.  When the analysis was restricted to treated and suppressed individuals only, the results remained the same.

Certain inflammatory markers such as CMV IgG, TNF-α, and neopterin (a marker of plaque instability) were independently predictive of endothelial dysfunction in HIV-infected individuals. CMV-specific T cell activation was independently associated with worsened RH. Unlike FMD, RH measures microvascular function and thus could explain the different findings between the two outcomes. Interventions targeted at reducing inflammation particularly in the setting of CMV infection may improve endothelial function and decrease HIV-associated CVD.